Search results
Showing 1561 to 1575 of 8212 results
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
NICE is unable to make a recommendation on mirabegron (Betmiga) for treating neurogenic detrusor activity in people 3 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1100
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.
Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.
NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is because BeiGene has requested a delay to the evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA978
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
Evidence-based recommendations on lorlatinib (Lorviqua) for treating ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor in adults.
Show all sections
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.
NICE is unable to make a recommendation on sarilumab (Kevzara) for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1104